{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:58Z","timestamp":1785560278775,"version":"3.56.0"},"reference-count":31,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,7,31]]},"DOI":"10.1536\/ihj.25-600","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:10:49Z","timestamp":1785449449000},"page":"306-313","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Lipoprotein (a) in Japanese Patients with Acute Coronary Syndrome Surviving Primary Percutaneous Coronary Intervention to Discharge"],"prefix":"10.1536","volume":"67","author":[{"given":"Ryo","family":"Okubo","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kishigami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Tsubono","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Aikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014; 35: 2929.","DOI":"10.1093\/eurheartj\/ehu299"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Szummer K, Wallentin L, Lindhagen L, <i>et al<\/i>. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J 2017; 38: 3056-65.","DOI":"10.1093\/eurheartj\/ehx515"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mach F, Baigent C, Catapano AL, <i>et al<\/i>. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111-88.","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"4","unstructured":"4. Rao SV, O&apos;Donoghue ML, Ruel M, <i>et al<\/i>. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2025; 151: e771-862."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016; 4: 256.","DOI":"10.21037\/atm.2016.06.33"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-9.","DOI":"10.1001\/jama.2009.801"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Clarke R, Peden JF, Hopewell JC, <i>et al<\/i>. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-28.","DOI":"10.1056\/NEJMoa0902604"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kumakura H, Fujita K, Kanai H, <i>et al<\/i>. High-sensitivity C-reactive Protein, Lipoprotein(a) and Homocysteine are Risk Factors for Coronary Artery Disease in Japanese Patients with Peripheral Arterial Disease. J Atheroscler Thromb 2015; 22: 344-54.","DOI":"10.5551\/jat.25478"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bittner VA, Szarek M, Aylward PE, <i>et al<\/i>. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol 2020; 75: 133-44.","DOI":"10.1016\/j.jacc.2019.10.057"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Takahashi D, Wada H, Ogita M, <i>et al<\/i>. Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins. Am J Cardiol 2022; 168: 11-6.","DOI":"10.1016\/j.amjcard.2021.12.014"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Steg PG, Szarek M, Valgimigli M, <i>et al<\/i>. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. Can J Cardiol 2023; 39: 1315-24.","DOI":"10.1016\/j.cjca.2023.04.018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Park JS, Cho KH, Hong YJ, <i>et al<\/i>. Baseline Lipoprotein(a) Levels and Long-Term Cardiovascular Outcomes After Acute Myocardial Infarction. J Korean Med Sci 2023; 38: e102.","DOI":"10.3346\/jkms.2023.38.e102"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gencer B, Rigamonti F, Nanchen D, <i>et al<\/i>. Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. Eur J Clin Invest 2019; 49: e13117.","DOI":"10.1111\/eci.13117"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sang T, Cheng N, Dang A, <i>et al<\/i>. Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome. J Clin Lipidol 2021; 15: 466-76.","DOI":"10.1016\/j.jacl.2021.04.003"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117: 176-84.","DOI":"10.1161\/CIRCULATIONAHA.107.715698"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matsumoto Y, Daida H, Watanabe Y, <i>et al<\/i>. High level of lipoprotein(a) is a strong predictor for progression of coronary artery disease. J Atheroscler Thromb 1998; 5: 47-53.","DOI":"10.5551\/jat1994.5.47"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pare G, Caku A, McQueen M, <i>et al<\/i>. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. Circulation 2019; 139: 1472-82.","DOI":"10.1161\/CIRCULATIONAHA.118.034311"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shishikura D, Kataoka Y, Nicholls SJ, <i>et al<\/i>. Characterization of lipidic plaque features in association with LDL-C &lt; 70 mg\/dL and lipoprotein(a) &lt; 50 mg\/dL. J Clin Lipidol 2025; 19: 509-20.","DOI":"10.1016\/j.jacl.2024.12.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 2013; 48: 452-8.","DOI":"10.1038\/bmt.2012.244"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Schwartz GG, Ballantyne CM, Barter PJ, <i>et al<\/i>. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol 2018; 3: 164-8.","DOI":"10.1001\/jamacardio.2017.3833"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Puri R, Ballantyne CM, Hoogeveen RC, <i>et al<\/i>. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis 2017; 263: 137-44.","DOI":"10.1016\/j.atherosclerosis.2017.06.026"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Schwartz GG, Szarek M, Bittner VA, <i>et al<\/i>. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol 2021; 78: 421-33.","DOI":"10.1016\/j.jacc.2021.04.102"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lanktree MB, Anand SS, Yusuf S, Hegele RA, Investigators S. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 2010; 3: 39-46.","DOI":"10.1161\/CIRCGENETICS.109.907642"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Guan W, Cao J, Steffen BT, <i>et al<\/i>. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35: 996-1001.","DOI":"10.1161\/ATVBAHA.114.304785"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Yoshida H, Kroes M, Sakai Y, <i>et al<\/i>. Lipoprotein(a) in Japanese Patients With Cardiovascular Disease: A Systematic Review. JACC Asia 2025; 5: 1525-39.","DOI":"10.1016\/j.jacasi.2025.08.017"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rodriguez EC, Kallmeyer A, Tarin N, <i>et al<\/i>. Beyond secondary prevention drugs: Added benefit in survival and events of a healthy lifestyle in patients after an acute coronary syndrome. Am J Prev Cardiol 2025; 21: 100923.","DOI":"10.1016\/j.ajpc.2024.100923"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Nicholls SJ, Nissen SE, Fleming C, <i>et al<\/i>. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA 2023; 330: 1042-53.","DOI":"10.1001\/jama.2023.16503"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Cho L, Nicholls SJ, Nordestgaard BG, <i>et al<\/i>. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). Am Heart J 2025; 287: 1-9.","DOI":"10.1016\/j.ahj.2025.03.019"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. O&apos;Donoghue ML, G L\u00f3pez JA, Knusel B, <i>et al<\/i>. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J 2022; 251: 61-9.","DOI":"10.1016\/j.ahj.2022.05.004"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Afshar M, Pilote L, Dufresne L, Engert JC, Thanassoulis G. Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). J Am Heart Assoc 2016; 5: e003012.","DOI":"10.1161\/JAHA.115.003012"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Afshar M, Rong J, Zhan Y, <i>et al<\/i>. Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study. J Am Heart Assoc 2020; 9: e014711.","DOI":"10.1161\/JAHA.119.014711"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/4\/67_25-600\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:14:08Z","timestamp":1785557648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/4\/67_25-600\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.25-600","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"25-600"}}